logo
OWNx Launches Industry-First 'EDGE' Membership: Buy Gold, Silver, and Platinum At-Cost with Zero Fees

OWNx Launches Industry-First 'EDGE' Membership: Buy Gold, Silver, and Platinum At-Cost with Zero Fees

Business Upturn21-04-2025

Lawrence, KS , April 21, 2025 (GLOBE NEWSWIRE) — OWNx, a pioneer in precious metals investment since 2008, today announced the launch of OWNx EDGE, a revolutionary membership service that transforms where to buy gold, silver, and platinum by providing investors direct access at wholesale prices with zero markups or hidden fees.
OWNx
In an industry where retail investors searching for where to buy precious metals typically pay 5-25% above spot price, OWNx EDGE delivers unprecedented value by eliminating dealer markups entirely. For just $14.99 monthly or $149 annually, members gain access to institutional-level pricing previously available only to bulk purchasers, creating what many experts consider the best way to buy gold and other precious metals.
Sign up before Memorial Day (May 26, 2025) and lock in the EDGE annual membership for just $99 forever – a savings of over 33% off our standard annual rate. After this promotional period ends, standard pricing will apply for new members.
'With OWNx Edge, we're redefining how individuals invest in gold and silver,' said Josh McCleary, Co-Founder and COO of OWNx. 'For too long, everyday investors trying to invest in silver or gold have paid unnecessary premiums. Now, they can own precious metals at cost—no markup, no middlemen. It's a game-changer in the industry, and we're proud to make this level of access available to anyone who values transparency, security, and real ownership.'
Real Investment Impact
The savings from eliminating markups are substantial. A $50,000 investment in gold with traditional dealers could incur $1,750 to $5,000 in hidden fees and markups. With OWNx EDGE, investors pay only the flat membership fee, allowing them to put up to $4,851 more into actual gold compared to competitors.
Key Features of OWNx EDGE: Zero Markup Pricing: Members purchase precious metals at the same cost as institutional buyers Fractional Ownership: Access to low-premium large bars without minimum purchase requirements Secure, Insured Storage: Metals stored in non-bank depositories in Delaware or Texas User-Friendly Platform: Seamless online dashboard and mobile app for buying and tracking metals Low Storage Costs: Just 0.6% per year (0.5% for IRA holdings) Optional Physical Redemption: Holdings can be exchanged for physical delivery (additional costs apply) IRA Integration: OWNx EDGE included free with an OWNx Precious Metals IRA
OWNx
New Rewards Program Launches Alongside EDGE
Alongside the EDGE service, OWNx is introducing an enhanced rewards program that enables members to earn passive income through referrals. Members receive 50% commission for the first year of any new subscription they refer, followed by 20% commission every year after for as long as the referred member remains active.
'From the day we launched our technology platform, OWNx clients wanted an easy way to share what they found with friends and family,' explained McCleary. 'With our new rewards structure tied to OWNx EDGE, members can build a substantial recurring income stream while helping others access precious metals at the lowest possible prices.'
About OWNx
Founded in 2008, OWNx is a pioneering platform in the precious metals market, offering secure and innovative solutions for those looking to invest in gold, silver, platinum. With a focus on technology-driven solutions, OWNx has transformed where to buy precious metals by providing automatic purchase options, secure storage, and instant trading capabilities, empowering individuals to diversify their portfolios with confidence. The company's OWNx Precious Metals IRA allows investors to include physical precious metals in their retirement planning while enjoying the benefits of EDGE membership at no additional cost.
###
Contact Information
Josh McClearyCo-Founder and COO
[email protected]
Lawrence, Kansas

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Clinical Laboratory Molecular Diagnostics for Infectious Disease Market Research 2025-2029: Biotechnology and Genomics Drive Advancements, Impact of Multiplex Assays in Diagnosis and Treatment
Clinical Laboratory Molecular Diagnostics for Infectious Disease Market Research 2025-2029: Biotechnology and Genomics Drive Advancements, Impact of Multiplex Assays in Diagnosis and Treatment

Yahoo

time24 minutes ago

  • Yahoo

Clinical Laboratory Molecular Diagnostics for Infectious Disease Market Research 2025-2029: Biotechnology and Genomics Drive Advancements, Impact of Multiplex Assays in Diagnosis and Treatment

Discover the future of the Molecular Diagnostics - Infectious Disease sector with our comprehensive report. Explore how multiplex assays and rapid testing are transforming diagnosis and treatment amidst the boom in biotechnology and genomics. This detailed analysis covers dynamic trends such as pathogen evolution, globalization, and climate change impacts. Benefit from extensive insights, including U.S. Medicare Fee Schedules, and detailed global data. Equip your organization with expert knowledge today. Dublin, June 06, 2025 (GLOBE NEWSWIRE) -- The "Clinical Laboratory Molecular Diagnostics for Infectious Disease Markets 2025-2029: Strategies, Trends, and Forecasts by Application, Place and Country with Market Analysis & Executive Guides" report has been added to offering. The Molecular Diagnostics - Infectious Disease sector of the clinical diagnostics industry is poised for further growth. A market that just keeps on growing but is becoming more complex and segmented. Find out what's happening in this informative report - and find out about the impact of multiplex assays which threaten to change diagnosis and treatment forever. The report has hundreds of pages of information including a complete list of Current United States Medicare Fee Payment Schedules to help sharpen your pricing along with the most frequently used and billed tests. The report includes detailed breakouts for 15 countries and 4 regions. A detailed breakout for any country in the world is available to purchasers of the report. This research makes you the expert in your organization. Assistance and additional specific data is provided without additional charges. All report data is available in Excel format on request. Exciting technical developments especially in the seesaw between nucleic acid testing and immunoassay, hold the promise of a dynamic, growing and evolving world market that holds the promise of diagnostics taking the lead in infectious disease eradication. Infectious disease testing directly benefits from the explosion in biotechnology, especially genomics. Learn all about it in this report. A range of dynamic trends are pushing market growth and company valuations. Trends like: Multiplex testing Pathogen evolution and pandemics Biotechnology advances in genetics Climate change Globalization The rise of rapid testing Key Topics Covered: 1 Market Guides1.1 Situation Analysis2 Introduction and Market Definition2.1 Market Definition2.1.1 Market Size2.1.2 Currency2.1.3 Years2.2 Methodology2.2.1 Methodology2.2.2 Sources2.2.3 Authors2.3 Perspective: Healthcare Spending2.3.1 Global Healthcare Spending2.3.2 Spending on Healthcare and Pharmaceuticals2.3.3 Spending on Diagnostics2.3.4 Important Role of Insurance for Medical Services2.4 The Nature of the IVD Product2.4.1 Features Overview2.4.2 The Misunderstood Feature2.4.3 Regulation2.4.4 The Newest Feature2.4.5 The Oldest Feature2.4.6 All About Scope2.4.7 Why Turnaround is Becoming More Important2.4.8 The Role of Trust2.5 The IVD Product of the Future3 Infectious Diseases - Guide to the Pathogens3.1 Infectious Disease Pathogens - The Big Picture3.1.1 Viruses3.1.2 Bacteria3.1.3 Fungi3.1.4 Parasites3.1.5 Prions3.1.6 Virulence3.1.7 Transmission3.2 The Coronavirus3.2.1 Severe acute respiratory syndrome (SARS)3.2.2 Middle East respiratory syndrome (MERS)3.2.3 COVID-19. The SARS CoV 2 Virus3.2.3.1 Signs and symptoms3.2.3.2 Transmission3.2.3.3 Diagnosis3.2.3.4 Prevention3.2.3.5 Management3.2.3.6 Prognosis4 Industry Overview4.1 Players in a Dynamic Market4.1.1 Academic Research Lab4.1.2 Diagnostic Test Developer4.1.3 Instrumentation Supplier4.1.4 Chemical/Reagent Supplier4.1.5 Pathology Supplier4.1.6 Independent Clinical Laboratory4.1.7 Public National/regional Laboratory4.1.8 Hospital Laboratory4.1.9 Physicians Office Lab (POLS)4.1.10 Audit Body4.1.11 Certification Body4.2 The Clinical Laboratory Market Segments4.2.1 Traditional Market Segmentation4.2.2 Laboratory Focus and Segmentation4.2.3 Segmenting the Syndromic Testing Market4.3 Industry Structure4.3.1 Hospital Testing Share4.3.2 Economies of Scale4.3.3 Hospital vs. Central Lab4.3.4 Physician Office Lab's4.3.5 Physician's and POCT5 Market Trends5.1 Factors Driving Growth5.1.1 The Nucleic Acid Impact5.1.2 Population Dynamics5.1.3 The Developing World5.1.4 Decentralization5.1.5 Self Testing5.1.6 The Need for Speed5.2 Factors Limiting Growth5.2.1 Costs and Experience Curve Effects5.2.2 The Role of ID Prevalence5.2.3 Wellness5.2.4 The Impact of Living Standards5.3 Instrumentation, Automation and Diagnostic Trends5.3.1 Traditional Automation and Centralization5.3.2 The New Automation, Decentralization and Point of Care5.3.3 Instruments Key to Market Share5.3.4 Bioinformatics Plays a Role5.3.5 PCR Takes Command5.3.6 Next Generation Sequencing Fuels a Revolution5.3.7 NGS Impact on Pricing5.3.8 Whole Genome Sequencing, A Brave New World5.3.9 Companion Diagnostics Blurs Diagnosis and Treatment6 Clinical Laboratory MDx Infectious Disease Recent Developments6.1 Recent Developments - Importance and How to Use This Section6.1.1 Importance of These Developments6.1.2 How to Use This Section6.2 Presymptom Health Nabs Funding for Sepsis Test6.3 FDA Clears BioMerieux GI Panel6.4 Rapid Infection Diagnostic Launches BSIDx6.5 Biotia's AI-, Sequencing-Based UTI Test approved6.6 Delve Bio, Broad Clinical Labs Partner for Metagenomic6.7 Roche Respiratory Panel Receives FDA EUA6.8 Genetic Signatures Gets Approval for GI Parasite Panel6.9 Diasorin Expands Respiratory Panel6.10 BioMerieux Outlines MDx-Driven Growth6.11 T2 Biosystems Gets Extended T2Bacteria Panel6.12 Diasorin Aims to Deliver Updated Instruments, New Assays6.13 Oxford Nanopore Nabs Investment From BioMerieux6.14 Day Zero Diagnostics Closes Financing Round6.15 Spindiag Seeks Investors for Rapid PCR System6.16 Sorrento Therapeutics Nabs Contract for Dx Platform6.17 Kephera Planning Menu of Infectious Disease Tests6.18 Oxford Nanopore and BioMerieux to Develop IDDx6.19 SD Biosensor Eyes Global Expansion6.20 Selux Dx Next Gen Phenotyping Gets FDA Clearance6.21 Takara Developing High-Throughput Multiplex Panels6.22 BioGX Debuts New Point-of-Care Molecular Testing System6.23 Nanopath MDx Platform Providing 15-Minute Results6.24 ProtonDx Commercializing Rapid MDx Instrument6.25 Hologic Obtains CE Mark for MDx Epstein-Barr, BK Virus Assays6.26 Pathogenomix Infectious Disease Platform Uses Cloud-Based Analytics, NGS6.27 Accelerate Diagnostics Anticipates Growth6.28 Lumos Diagnostics Expanding Test Portfolio6.29 Study Validates Karius Cell-Free DNA to Detect Hundreds of Pathogens7 Key Companies7.1 Abbott Laboratories7.2 Agilent7.3 Altona Diagnostics7.4 Anitoa7.5 Autonomous Medical Devices7.6 Beckman Coulter Diagnostics (Danaher)7.7 Becton, Dickinson and Company7.8 BioGX7.9 Biomatik7.10 bioMerieux Diagnostics7.11 Bio-Rad Laboratories, Inc.7.12 Cepheid (Danaher)7.13 Diasorin S.p.A.7.14 DNAe7.15 Flow Health7.16 Global Access Diagnostics7.17 Great Basin Scientific, Inc.7.18 Hologic7.19 Novacyt7.20 Novus Diagnostics7.21 Oncimmune7.22 One Codex7.23 OraSure Technologies7.24 Prometheus Laboratories7.25 Qiagen7.26 QuidelOrtho7.27 R-Biopharm AG7.28 Response Biomedical7.29 Revvity7.30 Roche Diagnostics7.31 Siemens Healthineers7.32 Thermo Fisher Scientific7.33 Vela Diagnostics7.34 Veredus Laboratories7.35 YD Diagnostics7.36 Zhejiang Orient Gene Biotech8 The Global Market for Clinical Laboratory MDx Infectious Disease8.1 Global Market Overview by Country8.2 Global Market by Application - Overview8.3 Global Market by Place - Overview9 Global Clinical Laboratory MDx Infectious Disease Markets - By Application9.1 Respiratory9.2 Blood Borne Virus9.3 Transplant9.4 Hospital Acquired Infections9.5 Reproductive Health9.6 C19 Singleplex9.7 Meningitis9.8 Gastrointestinal9.9 Tropical10 Global Clinical Laboratory MDx Infectious Disease Markets - By Place10.1 Hospital Lab10.2 Outpatient Lab10.3 Point of Care10.4 Other Place11 Appendices11.1 Growth of Approved IVD Test Menu11.2 Growth of Approved Average IVD Test Fee11.3 The Most Used IVD Assays11.4 The Highest Grossing Assays11.5 Laboratory Fees Schedule For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

2025 Aromatherapy and Essential Oils Market Analysis Report: Holistic-Well-Being, Transparency, Sustainable Practices, Certifications and Claims, and AI-Powered Personalized Scents
2025 Aromatherapy and Essential Oils Market Analysis Report: Holistic-Well-Being, Transparency, Sustainable Practices, Certifications and Claims, and AI-Powered Personalized Scents

Yahoo

time24 minutes ago

  • Yahoo

2025 Aromatherapy and Essential Oils Market Analysis Report: Holistic-Well-Being, Transparency, Sustainable Practices, Certifications and Claims, and AI-Powered Personalized Scents

The Global Aromatherapy and Essential Oils Market is poised for substantial growth, with a forecasted CAGR over 6%, driven by heightened well-being awareness and social media influence. Valued at over $8 billion in 2024, North America leads with 45% market share, fueled by holistic wellness trends. Asia-Pacific follows closely, propelled by demographic changes and Gen Z's health focus. Companies prioritizing personalized, natural solutions will thrive. The comprehensive report includes market size, revenue forecasts, trends, and more. Dublin, June 06, 2025 (GLOBE NEWSWIRE) -- The "2025 Aromatherapy and Essential Oils Market" report has been added to offering. The Global Aromatherapy and Essential Oils Market is set for consistent growth, with a projected CAGR exceeding 6% during 2024-2031 This expansion is driven by a growing emphasis on well-being, the rise of the she economy, the influence of social media, direct selling model and the increasing adoption of complementary and alternative medicine. The global market was valued over $8 billion in 2024. North America made up the largest portion of the global market with over 45% in revenues in 2024, followed by Asia Pacific with over 40% of revenues. The North American market is being driven by growing consumer interest in holistic wellness and natural remedies. As people become more focused on mental and emotional health, essential oils are being used for anxiety relief, stress management, and mindfulness. The rising awareness of sleep hygiene has also fueled demand for essential oil blends that promote relaxation and better sleep. Wellness brands are responding by offering more specialized products. The Asia-Pacific region is witnessing significant demographic and lifestyle shifts that are reshaping the wellness industry. Two primary factors driving this transformation are the aging population and the growing health-consciousness of younger generations like Gen Z. These changes are boosting the demand for products and services focusing on overall well-being. As European consumers continue to prioritize personalized and natural wellness solutions, the aromatherapy and essential oils market is poised for sustained growth. Companies that align their product lines with specific consumer needs, while emphasizing safety, sustainability, and quality, will remain competitive in this evolving landscape. Report Scope A comprehensive analysis of the Global Aromatherapy and Essential Oils Market for North America, Latin America, Europe, Asia-Pacific, and Rest of World, which includes market sizing, market share by competitor, drivers, restraints, regional trends and revenue forecasts to 2031. Essential oils are defined as natural oils, typically obtained by distillation, having the characteristic fragrance from the plant or other source extraction. Technically, aromatherapy means the use of aromas as therapy or the use of aromas for their healing properties. However, there is an increasing move to use the term 'essential oils' (which more accurately describes the existing market) as the therapeutic use of essential oils based on their aroma and properties, which includes internal use of the oils. For purposes of this research, only essential oils that are used for health and wellness and relaxation purposes via topical application, inhalation, diffusion, and ingestion have been included. The report includes the following information: Market Size, Growth Rate, Revenue Forecast (2024-2031) Revenue Share by Segment (distribution channel, product type, customer segment) Growth Drivers & Restraints Competitive Factors Industry Challenges Market Trends Regional Trends Pricing Trends Distribution Trends Regulatory Information Major Company Profiles Every report purchase comes with 1 hour of Analyst Inquiry Time for a phone call with the analysts. This can be used for strategic advice, consultation, or addressing issues in your business and linking them to a solution. Analyst Inquiry Time must be used within 45 days of report purchase. Key Topics Covered: 1. Research Scope, Methodology, Definition 2. Executive Summary Major Data Points - Global Revenue by Region, 2024 Revenue, Global, 2019-2024 3. Competitive Factors 4. Consumer Behavior 5. Market Drivers and Impact 6. Market Restraints and Impact 7. Global Trends Holistic-Well-Being Transparency Sustainable Practices Certifications and Claims AI-Powered Personalized Scents 8. Market Data - Global Total Market Revenue and Forecast Market Share by Company Distribution Share Analysis Market Share by Product Type 9. Competitive Landscape dOTERRA International, LLC Young Living Essential Oils, LC Melaleuca, Inc. 10. North America Major Data Points Consumer Behavior Market Drivers and Impact Market Restraints and Impact Market Trends Market Data 11. Asia-Pacific Major Data Points Consumer Behavior Market Drivers and Impact Market Restraints and Impact Market Trends Major Markets - China, South Korea, Japan, and Australia Market Data 12. Europe Major Data Points Consumer Behavior Market Drivers and Impact Market Restraints and Impact Market Trends Major Markets - Germany, and United Kingdom Market Data 13. Latin America Major Data Point Consumer Behavior Market Drivers and Impact Market Restrains and Impact Market Trends Market Data 14. Market Data - Rest of the World Companies Featured doTERRA Young Living Melaleuca Inc. Ryohin Keikaku Co. Ltd. Plant Therapy Neal's Yard Remedies Jurlique Saje Natural Business Inc. Frontier Co-op (Aura Cacia) Rocky Mountain Oils Eden Botanicals Melaleuca Plant Therapy rareEssence Eden Gardens Essential oils Nature Packaged Swiss Just America Exotic Aroma Perfect Potion Essentials Quintis @aroma Primavera Life GmbH First Natural Brands (Tisserand) Farfalla Terra Gaia Florihana Neom well-being Aromatherapy Associates Absolute Aromas For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

Huize Holding Limited Reports First Quarter 2025 Unaudited Financial Results
Huize Holding Limited Reports First Quarter 2025 Unaudited Financial Results

Yahoo

timean hour ago

  • Yahoo

Huize Holding Limited Reports First Quarter 2025 Unaudited Financial Results

SHENZHEN, China, June 06, 2025 (GLOBE NEWSWIRE) -- Huize Holding Limited, ('Huize', the 'Company' or 'we') (NASDAQ: HUIZ), a leading insurance technology platform connecting consumers, insurance carriers and distribution partners digitally through data-driven and AI-powered solutions in Asia, today announced its unaudited financial results for the quarter ended March 31, 2025. First Quarter 2025 Financial and Operational Highlights Robust growth in insurance premiums: Gross written premiums ('GWP') reached RMB1,437.3 million for the first quarter of 2025, representing an increase of 37.8% from RMB1,043.0 million in the final quarter of 2024. First year premiums ('FYP') also rose 30.9% sequentially to RMB730.4 million in the first quarter of 2025. Increases in premiums were driven primarily by our high-quality customer base, sustainably high persistency ratios, and the diverse insurance product offerings that we provide on our platform. Improving operational efficiency: Total operating expenses declined by 28.9% sequentially to RMB82.7 million in the first quarter of 2025. Our expense-to-income ratio improved significantly from 40.7% in the final quarter of 2024 to 29.1% in the first quarter of 2025, reflecting the operational efficiency improvement driven by our recent cost-optimization initiatives and the integration of our proprietary AI into everyday workstreams. The cumulative number of insurance clients served increased to 11.0 million as of March 31, 2025. Huize cooperated with 143 insurer partners in mainland China and internationally, including 83 life and health insurance companies and 60 property and casualty insurance companies, as of March 31, 2025. As of March 31, 2025, cash and cash equivalents were RMB201.7 million (US$27.8 million). Mr. Cunjun Ma, Founder and CEO of Huize, said, 'We are pleased to deliver another quarter of resilient business results, with operating revenue exceeded RMB280 million, while gross written premiums and first-year premiums facilitated on our platform increasing 38% and 31% sequentially, reaching RMB1.4 billion and RMB730 million, respectively.' 'Throughout the quarter, we remained focused on acquiring and serving high-quality, mass-affluent customers. The average age of customers who purchased long-term insurance products in the quarter was 35.0 years old, among which 66.4% were in higher-tier cities. By the end of February, our 13th and 25th month persistency ratios for long-term life and health insurance products remained at industry-high levels of more than 95%, reflecting the high quality of customers we acquired through various channels.' 'We continue to develop and launch differentiated customized products with insurer partners. Market demand for wealth protection solutions has intensified amid a declining interest rate environment. In response, we partnered with New China Life to launch 'Bliss No. 3,' a savings product striving to achieve sustainable returns for customers. Additionally, we expanded our portfolio of customized participating products. Building on the 'Fu Man Jia' series co-launched with Aviva-COFCO, we partnered with Cathay Lujiazui Life Insurance on 'Jin Man Yi Zu No.6', a participating incremental whole life insurance product. This was followed by the launch of 'Xing Hai Hui Xuan', a participating annuity product co-developed with Pramerica Fosun Life Insurance. These customized products were designed to cater to the industry-wide demand shift from fixed returns to floating-returns, further solidifying our leadership in China's participating insurance segment.' 'Our proprietary AI solutions are increasingly integrated across our operations, enhancing service efficiency and supporting sustainable growth. Notably, our expense-to-income ratio fell by 11.5 percentage points sequentially, reaching 29.1% in the first quarter of 2025. With private large-language model deployments, we are not only realizing meaningful cost savings, but also reinforcing the security and effectiveness of our data capabilities, ensuring regulatory compliance.' 'During the quarter, we launched an AI-powered smart portal on Huize's app, offering 24/7 insurance agent support. Our AI services now cover key customer lifecycle touchpoints including policy inquiries and product matching, serving an average of over 15,000 users daily. We are also revolutionizing after-sales claims processing through Xiao Ma Claim's AI agents, achieving end-to-end automation of claims reporting, review, and payout. This innovation is expected to reduce processing time on Xiao Ma Flash Claim from one day to one hour upon full rollout. In the first quarter, Xiao Ma Claim facilitated RMB190 million in claims across 36,000 cases, providing customers with efficient and reliable insurance claim services.' First Quarter 2025 Financial Results GWP and operating revenue GWP facilitated on our platform was RMB1,437.3 million (US$198.1 million) in the first quarter of 2025, a decrease of 16.3% from RMB1,718.0 million in the same period of 2024. Within GWP facilitated in the first quarter of 2025, FYP accounted for RMB730.4 million (or 50.8% of total GWP), a decrease of 14.8% year-over-year. Renewal premiums accounted for RMB706.8 million (or 49.2% of total GWP), a decrease of 17.9% year-over-year. Operating revenue was RMB283.8 million (US$39.1 million) in the first quarter of 2025, a decrease of 8.5% from RMB310.3 million in the same period of 2024. The decrease was primarily driven by the decrease in FYP facilitated. Operating costs Operating costs were RMB210.5 million (US$29.0 million) in the first quarter of 2025, a decrease of 4.4% from RMB220.2 million in the same period of 2024, primarily due to a decrease in channel expenses. Operating expenses Selling expenses were RMB47.3 million (US$6.5 million) in the first quarter of 2025, an increase of 7.0% from RMB44.2 million in the same period of 2024, primarily due to an increase in advertising and marketing expenses. General and administrative expenses were RMB21.9 million (US$3.0 million) in the first quarter of 2025, a decrease of 3.2% from RMB22.6 million in the same period of 2024. This decrease was primarily due to a decrease in rental and utilities expenses. Research and development expenses were RMB13.5 million (US$1.9 million) in the first quarter of 2025, a decrease of 6.3% from RMB14.4 million in the same period of 2024, primarily due to a decrease in rental and utilities expenses. Net loss and non-GAAP net loss for the period Net loss attributable to common shareholders was RMB8.6 million (US$1.2 million) in the first quarter of 2025, compared to net profit attributable to common shareholders of RMB6.9 million in the same period of 2024. Non-GAAP net loss attributable to common shareholders1 was RMB10.9 million (US$1.5 million) in the first quarter of 2025, compared to non-GAAP net profit attributable to common shareholders of RMB4.4 million in the same period of 2024. Cash and cash equivalents As of March 31, 2025, the Company's cash and cash equivalents amounted to RMB201.7 million (US$27.8 million), compared to RMB233.2 million as of December 31, 2024. Conference Call The Company's management team will hold an earnings conference call at 8:00 A.M. Eastern Time on Friday, June 6, 2025 (8:00 P.M. Beijing/Hong Kong Time on Friday, June 6, 2025). Details for the conference call are as follows: Event Title: Huize Holding Limited's First Quarter 2025 Earnings Conference CallRegistration Link: All participants must use the link provided above to complete the online registration process in advance of the conference call. Upon registration, each participant will receive a confirmation email containing dial-in numbers and a unique access PIN, which will be used to join the conference call. Additionally, a live and archived webcast of the conference call will also be available on the Company's investor relations website at About Huize Holding Limited Huize Holding Limited is a leading insurance technology platform connecting consumers, insurance carriers and distribution partners digitally through data-driven and AI-powered solutions in Asia. Targeting mass affluent consumers, Huize is dedicated to serving consumers for their life-long insurance needs. Its online-to-offline integrated insurance ecosystem covers the entire insurance life cycle and offers consumers a wide spectrum of insurance products, one-stop services, and a streamlined transaction experience across all scenarios. By leveraging AI, data analytics, and digital capabilities, Huize empowers the insurance service chain with proprietary technology-enabled solutions for insurance consultation, user engagement, marketing, risk management, and claims service. For more information, please visit or follow us on social media via LinkedIn ( X( and Webull( Use of Non-GAAP Financial Measure Statement In evaluating our business, we consider and use non-GAAP net profit/(loss) attributable to common shareholders as a supplemental measure to review and assess our operating performance. The presentation of the non-GAAP financial measure is not intended to be considered in isolation or as a substitute for the financial information prepared and presented in accordance with U.S. GAAP. We define non-GAAP net profit/(loss) attributable to common shareholders as net profit/(loss) attributable to common shareholders excluding share-based compensation expenses. Such adjustments have no impact on income tax because either the non-GAAP adjustments were recorded at entities located in tax free jurisdictions, such as the Cayman Islands or because the non-GAAP adjustments were recorded at operating entities located in the PRC for which the non-GAAP adjustments were not deductible for tax purposes. We present the non-GAAP financial measure because it is used by our management to evaluate our operating performance and formulate business plans. Non-GAAP net profit/(loss) attributable to common shareholders enables our management to assess our operating results without considering the impact of share-based compensation expenses. We also believe that the use of this non-GAAP financial measure facilitates investors' assessment of our operating performance. This non-GAAP financial measure is not defined under U.S. GAAP and is not presented in accordance with U.S. GAAP. The non-GAAP financial measure has limitations as an analytical tool. One of the key limitations of using adjusted net profit/(loss) attributable to common shareholders is that it does not reflect all items of income and expense that affect our operations. Further, the non-GAAP financial measure may differ from the non-GAAP financial information used by other companies, including peer companies, and therefore their comparability may be limited. The non-GAAP financial measure should not be considered in isolation or construed as an alternative to net profit/(loss) attributable to common shareholders or any other measure of performance or as an indicator of our operating performance. Investors are encouraged to review the historical non-GAAP financial measure in light of the most directly comparable GAAP measure, as shown below. The non-GAAP financial measure presented here may not be comparable to similarly titled measure presented by other companies. Other companies may calculate similarly titled measures differently, limiting the usefulness of such measures when analyzing our data comparatively. We encourage investors and others to review our financial information in its entirety and not rely on a single financial measure. Exchange Rate Information This announcement contains translations of certain RMB amounts into U.S. dollars at a specified rate solely for the convenience of the reader. Unless otherwise noted, all translations from RMB to U.S. dollars and from U.S. dollars to RMB are made at a rate of RMB7.2567 to US$1.00, the exchange rate on March 31, 2025, set forth in the H.10 statistical release of the Federal Reserve Board. The Company makes no representation that the RMB or U.S. dollars amounts referred could be converted into U.S. dollars or RMB, as the case may be, at any particular rate or at all. Safe Harbor Statement This announcement contains forward-looking statements. These statements are made under the 'safe harbor' provisions of the U.S. Private Securities Litigation Reform Act of 1995. Statements that are not historical facts, including statements about Huize's beliefs and expectations, are forward-looking statements. These forward-looking statements can be identified by terminology such as 'will,' 'expects,' 'anticipates,' 'future,' 'intends,' 'plans,' 'believes,' 'estimates,' 'confident' and similar statements. Among other things, business outlook and quotations from management in this announcement, contain forward-looking statements. Huize may also make written or oral forward-looking statements in its periodic reports to the U.S. Securities and Exchange Commission (the 'SEC'), in its annual report to shareholders, in press releases and other written materials and in oral statements made by its officers, directors or employees to third parties. Forward-looking statements involve inherent risks and uncertainties. A number of factors could cause actual results to differ materially from those contained in any forward-looking statement, including but not limited to the following: Huize's goal and strategies; Huize's expansion plans; Huize's future business development, financial condition and results of operations; Huize's expectation regarding the demand for, and market acceptance of, its online insurance products; Huize's expectations regarding its relationship with insurer partners and insurance clients and other parties it collaborates with; general economic and business conditions; and assumptions underlying or related to any of the foregoing. Further information regarding these and other risks is included in Huize's filings with the SEC. All information provided in this press release is as of the date of this press release, and Huize does not undertake any obligation to update any forward-looking statement, except as required under applicable law. For investor and media inquiries, please contact: Investor RelationsKenny LoInvestor Relations Managerinvestor@ Media Relationsmediacenter@ Christensen AdvisoryIn ChinaMs. Dee WangPhone: +86-10-5900-1548Email: In Linda BergkampPhone: +1-480-614-3004Email: Holding LimitedUnaudited Condensed Consolidated Balance Sheets(all amounts in thousands, except for share and per share data) As of December 31, As of March 31, 2024 2025 RMB RMB USD Assets Current assets Cash and cash equivalents 233,207 201,708 27,796 Restricted cash 61,708 54,525 7,514 Short-term investments 5,000 3,137 432 Contract assets, net of allowance for doubtful accounts 71,085 60,680 8,362 Accounts receivables, net of allowance for impairment 157,080 191,794 26,430 Insurance premium receivables 1,763 1,640 226 Amounts due from related parties 995 1,204 166 Prepaid expense and other receivables 68,171 68,225 9,402 Total current assets 599,009 582,913 80,328 Non-current assets Restricted cash 29,883 29,883 4,118 Contract assets, net of allowance for expected credit losses 28,435 24,195 3,334 Property, plant and equipment, net 47,083 44,590 6,145 Intangible assets, net 68,840 69,785 9,617 Long-term investments 66,716 69,132 9,527 Operating lease right-of-use assets 20,715 17,126 2,360 Goodwill 14,536 14,536 2,003 Other assets 8,981 8,700 1,199 Total non-current assets 285,189 277,947 38,303 Total assets 884,198 860,860 118,631 Liabilities and Shareholders' Equity Current liabilities Short-term borrowings 50,000 53,000 7,304 Accounts payable 202,054 202,697 27,932 Insurance premium payables 56,042 47,531 6,550 Other payables and accrued expenses 44,434 33,446 4,606 Payroll and welfare payable 41,005 41,776 5,757 Income taxes payable 2,575 2,575 355 Operating lease liabilities 16,743 14,901 2,053 Amount due to related parties 2,495 - - Total current liabilities 415,348 395,926 54,557 Non-current liabilities Long-term borrowings - 6,990 963 Deferred tax liabilities 14,875 14,848 2,046 Operating lease liabilities 24,082 19,806 2,729 Payroll and welfare payable 649 305 42 Accounts payable - 2,713 374 Total non-current liabilities 39,606 44,662 6,154 Total liabilities 454,954 440,588 60,711 Shareholders' equity Class A common shares 63 63 9 Class B common shares 10 10 1 Treasury stock (29,513 ) (29,513 ) (4,067 ) Additional paid-in capital 909,930 909,930 125,392 Accumulated other comprehensive loss (12,864 ) (12,311 ) (1,697 ) Accumulated deficits (458,886 ) (467,473 ) (64,414 ) Total shareholders' equity attributable to Huize Holding Limited shareholders 408,740 400,706 55,224 Non-controlling interests 20,504 19,566 2,696 Total shareholders' equity 429,244 420,272 57,920 Total liabilities and shareholders' equity 884,198 860,860 118,631Huize Holding LimitedUnaudited Condensed Consolidated Statements of Comprehensive Income/(Loss) (all amounts in thousands, except for share and per share data) For the Three Months Ended March 31, 2024 2025 RMB RMB USD Operating revenue Brokerage income 301,882 271,850 37,462 Other income 8,430 11,939 1,645 Total operating revenue 310,312 283,789 39,107 Operating costs and expenses Cost of revenue (217,922 ) (209,012 ) (28,803 ) Other cost (2,273 ) (1,471 ) (203 ) Total operating costs (220,195 ) (210,483 ) (29,005 ) Selling expenses (44,205 ) (47,320 ) (6,521 ) General and administrative expenses (22,632 ) (21,905 ) (3,019 ) Research and development expenses (14,380 ) (13,471 ) (1,856 ) Total operating costs and expenses (301,412 ) (293,179 ) (40,402 ) Operating (loss)/profit 8,900 (9,390 ) (1,295 ) Other income/(expenses) Interest income 1,224 675 93 Unrealized exchange loss (293 ) (147 ) (19 ) Investment income/(loss) (2,325 ) 214 30 Others, net 1,950 736 101 (Loss)/profit before income tax, and share of loss of equity method investee 9,456 (7,912 ) (1,090 ) Income tax expense - (152 ) (21 ) Share of loss of equity method investee (767 ) (1,460 ) (201 ) Net (loss)/profit 8,689 (9,524 ) (1,312 ) Net (loss)/profit attributable to non-controlling interests 1,781 (937 ) (129 ) Net (loss)/profit attributable to Huize Holding Limited 6,908 (8,587 ) (1,183 ) Net (loss)/profit 8,689 (9,524 ) (1,312 ) Foreign currency translation adjustment, net of tax 1,499 553 76 Comprehensive (loss)/profit 10,188 (8,971 ) (1,236 ) Comprehensive (loss)/income attributable to non-controlling interests 1,781 (937 ) (129 ) Comprehensive (loss)/income attributable to Huize Holding Limited 8,407 (8,034 ) (1,107 ) Weighted average number of common shares used in computing net profit per share Basic and diluted 988,410,632 1,008,857,623 1,008,857,623 Net (loss)/profit per share attributable to common shareholders Basic and diluted 0.01 (0.01 ) (0.00 )Huize Holding LimitedUnaudited Reconciliations of GAAP and Non-GAAP Results(all amounts in thousands, except for share and per share data) For the Three Months Ended March 31, 2024 2025 RMB RMB USD Net (loss)/profit attributable to common shareholders 6,908 (8,587 ) (1,183 ) Share-basedcompensation expenses (2,558 ) (2,354 ) (324 ) Non-GAAP net (loss)/profit attributable to common shareholders 4,350 (10,941 ) (1,508 ) ______________________ 1 Non-GAAP net loss attributable to common shareholders is a non-GAAP financial measure. For more information, please see the section of 'Use of Non-GAAP Financial Measure Statement' and the table captioned 'Unaudited Reconciliations of GAAP and Non-GAAP Results' set forth at the end of this press in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store